(Q73349860)
Statements
Treatment with the platelet-activating factor antagonist TCV-309 in patients with severe systemic inflammatory response syndrome: a prospective, multi-center, double-blind, randomized phase II trial (English)
A M Froon
J W Greve
W A Buurman
C J van der Linden
H J Langemeijer
C Ulrich